1
|
Mattera A, Brignoli M, Coscia V, Fusco A, Diana V, Chianese R, De Michele A, Concilio C, Pariggiano I, Viscusi M, Calabrò P. P236 LONG TERM FOLLOW UP WITH A DRASTIC REDUCTION OF HOSPITALIZATION IN HEART FAILURE PATIENT WITH MULTIPLE AETIOLOGIES TREATED WITH CARDIAC CONTRACTILITY MODULATION THERAPY: A CASE REPORT. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Aims
Cardiac contractility modulation (CCM) shows to be a concrete therapeutic option in patients with symptomatic HF despite optimal medical therapy (OMT), with Left Ventricular Ejection Fraction (LVEF) between 25% and 45%, with narrow QRS complex (<130ms) for reduction of hospitalization and improvement Quality of life (QoL). This case aims to explore the effectiveness of CCM therapy in a patient affected by concomitant ischemic cardiomyopathy and cardiac amyloidosis (CA)
Methods
A 42–year–old man with Chronic HF secondary to both post–ischemic due to spontaneous coronary artery dissection (SCAD) and post alcoholic dilated cardiomyopathy was hospitalized at our department in February 2020 due to worsening HF (3rd HF hospitalization in the same year). The patient was a NYHA class III, with chronic kidney failure, a narrow QRS complex (100 ms) and a LVEF of 27% with familiar history of sudden death, already implanted with ICD. The patient resulted untreatable with Sacubitril/Valsartan, as it elicited strong hypotension. During current hospitalization the BNP value was 942,60 pg/ml, and the Quality of Life (QoL) evaluated from Minnesota Living with Heart Failure Questionnaire (MLHFQ) score was 72 points. Moreover, the patient underwent umbilical biopsy that confirmed the presence of amyloidosis. Thus, the CCM therapy device (Optimizer® Smart, Impulse Dynamics) was implanted to try to reduce HF symptoms and hospitalizations (Fig 1 A/B).
Results
The patient significantly improved as early as the first period after implantation. The 10–month in–office FU performed on December 2020 revealed in addition to the absence of new HF hospitalizations, a significant improvement in QoL and HF–symptoms, with a MLWHFQ score of 42, an enhancement to NHYA class II and even a slight decrease of BNP of 767 pg/ml. The echo exam revealed no significant changes in the EF, with an improvement of global longitudinal strain and no worsening of other hemodynamic parameters. A further FU performed in June 2021 showed continuous improvement of QoL (MLWHFQ = 25) e no HF hospitalizations.
Conclusions
In this patient affected by multiple cardiomyopathies, including CA, CCM therapy proved to improve its QoL with no HF hospital admissions since the implantation. The absence of significant echocardiographic worsening is a positive aspect, considering the patient’s status, the concomitant aetiologies, and the presence of amyloidosis, given its progressive and infiltrative nature.
Collapse
Affiliation(s)
- A Mattera
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - M Brignoli
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - V Coscia
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - A Fusco
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - V Diana
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - R Chianese
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - A De Michele
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - C Concilio
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - I Pariggiano
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - M Viscusi
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| | - P Calabrò
- AORN SANT‘ANNA E SAN SEBASTIANO, CASERTA; UNIVERSITÀ DELLA CAMPANIA – VANVITELLI, CASERTA
| |
Collapse
|
2
|
de Divitiis O, Di Somma S, Liguori V, Petitto M, Magnotta C, Ausiello M, Natale N, Brignoli M, Galderisi M. Effort blood pressure control in the course of antihypertensive treatment. Am J Med 1989; 87:46S-56S. [PMID: 2782327 DOI: 10.1016/0002-9343(89)90506-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In 30 patients with mild hypertension (diastolic blood pressure, 95 to 105 mmHg), the antihypertensive effect of rilmenidine 1 mg was compared in a double-blind study, with the effect of hydrochlorothiazide 25 mg. Patients not satisfactorily controlled received a combined therapy on the same doses of the two drugs used. Rilmenidine and hydrochlorothiazide induced a significant reduction (p = 0.01) of supine and erect systolic/diastolic blood pressure 23 hours after drug intake with no change in heart rate. This effect was due to a reduction in cardiac output (bioimpedance method) significant (p = 0.05) only for rilmenidine. Both drugs controlled the increase of effort systolic blood pressure in comparison with placebo on systemic vascular resistance treadmill exercise testing. Effort cardiac output was increased by each treatment in comparison with baseline values. Both at rest and on exertion, there was no effect on systemic vascular resistance induced by the two drugs. In a second group of 10 patients with moderate hypertension (diastolic blood pressure, 105 to 115 mmHg), rilmenidine 1 mg was administered in order to evaluate its efficacy and hemodynamic effects (bioimpedance and radionuclide ventriculography), at rest and during a lying cycloergometer effort test. The drug induced a significant decrease in blood pressure at rest and on exertion four hours after drug intake. This effect was due to a reduction (p = 0.05) in systemic vascular resistance, whereas cardiac output and heart rate remained unchanged. Our results show that the reduction in systolic/diastolic blood pressure induced by rilmenidine 1 mg is comparable with that induced by the well-known antihypertensive drug hydrochlorothiazide in mild hypertension. In moderate hypertension, the 1-mg dose appears to be insufficient in controlling the blood pressure in all patients. The drug exerts its antihypertensive effect through the normalization of the altered hemodynamic parameters of hypertension (high cardiac output and/or increased systemic vascular resistance). Rilmenidine also respects the physiologic increase in blood pressure and cardiac output on exertion.
Collapse
Affiliation(s)
- O de Divitiis
- Medical Physiopathology, University la Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
3
|
De Divitiis O, Liguori V, Di Somma S, Brignoli M, Ferraro S, Petitto M, Fazio S, Marsullo G, Salvatore M, Gradnik R. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. Eur Heart J 1987; 8 Suppl M:43-54. [PMID: 2967185 DOI: 10.1093/eurheartj/8.suppl_m.43] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
In order to verify the anti-ischaemic effect of a new beta-blocking agent, bisoprolol, a double blind parallel groups trial was carried out in comparison with verapamil. 26 patients with a history of spontaneous and/or effort angina were studied. After a two-week treatment with placebo, they were randomized in two groups. One group was treated for 4 weeks with bisoprolol 10 mg o.d. and for the following 4 weeks with bisoprolol 20 mg o.d. The other group received verapamil 80 mg t.i.d. for the first 4 weeks and 120 mg t.i.d. for the remaining 4 weeks. Throughout the study isosorbide dinitrate 20 mg b.i.d. was administered and sublingual nitroglycerin was allowed when necessary. 21 patients completed the study. Both bisoprolol and verapamil significantly reduced the number of angina episodes and nitroglycerin tablets consumption, as well as ischaemic episodes recorded on Holter ECG. The total number and severity of ectopic ventricular beats were reduced too. On multistage treadmill exercise test, both drugs increased effort time and time to ST depression = 1 mm, and reduced ST depression and double-product. The effect of bisoprolol on double product was greater than that of verapamil because of the better control of heart rate. The relationship ST/double product suggested that beta-blockers act essentially through the reduction of myocardial oxygen consumption and verapamil possibly with an additive effect on coronary circulation. Radionuclide ventriculography showed no deterioration of rest ventricular function with both drugs. In conclusion, bisoprolol and verapamil showed a satisfactory anti-ischaemic effect, with good tolerability.
Collapse
Affiliation(s)
- O De Divitiis
- Section of Cardioangiology, 2nd Medical School, University of Naples, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|